Genfit Zukünftiges Wachstum

Future Kriterienprüfungen 5/6

Genfit wird ein jährliches Gewinn- und Umsatzwachstum von 41.2% bzw. 20.1% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 2.1% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 5.5% betragen.

Wichtige Informationen

41.2%

Wachstumsrate der Gewinne

2.1%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	5.0%
Wachstumsrate der Einnahmen	20.1%
Zukünftige Eigenkapitalrendite	5.5%
Analystenabdeckung	Low
Zuletzt aktualisiert	14 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Genfit S.A. (EPA:GNFT) Not Doing Enough For Some Investors As Its Shares Slump 25%

Nov 16

We Think Shareholders Should Be Aware Of Some Factors Beyond Genfit's (EPA:GNFT) Profit

Sep 27

Genfit S.A. (EPA:GNFT) Held Back By Insufficient Growth Even After Shares Climb 26%

Sep 26

Growth Investors: Industry Analysts Just Upgraded Their Genfit S.A. (EPA:GNFT) Revenue Forecasts By 28%

Sep 24

Genfit (EPA:GNFT) Seems To Use Debt Quite Sensibly

Sep 22

Genfit S.A.'s (EPA:GNFT) Price Is Right But Growth Is Lacking After Shares Rocket 28%

May 23

New Forecasts: Here's What Analysts Think The Future Holds For Genfit S.A. (EPA:GNFT)

Sep 30

Downgrade: Here's How Analysts See Genfit S.A. (EPA:GNFT) Performing In The Near Term

Jun 29

Genfit's(EPA:GNFT) Share Price Is Down 85% Over The Past Five Years.

Mar 14

Is Genfit (EPA:GNFT) A Risky Investment?

Nov 28

Gewinn- und Umsatzwachstumsprognosen

ENXTPA:GNFT - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (EUR Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	75	12	7	8	4
12/31/2025	50	-18	12	12	4
12/31/2024	98	34	5	6	3
6/30/2024	80	22	-43	-42	N/A
3/31/2024	57	-3	-50	-48	N/A
12/31/2023	34	-29	-58	-55	N/A
9/30/2023	32	-32	-55	-53	N/A
6/30/2023	29	-34	-52	-50	N/A
3/31/2023	28	-29	-62	-61	N/A
12/31/2022	26	-24	-73	-73	N/A
9/30/2022	60	12	4	4	N/A
6/30/2022	94	48	80	80	N/A
3/31/2022	90	58	90	90	N/A
12/31/2021	85	67	99	100	N/A
9/30/2021	46	14	10	11	N/A
6/30/2021	6	-39	-79	-79	N/A
3/31/2021	7	-70	-88	-88	N/A
12/31/2020	9	-101	-97	-96	N/A
9/30/2020	24	-84	-73	-71	N/A
6/30/2020	39	-67	-49	-46	N/A
3/31/2020	39	-66	-49	-47	N/A
12/31/2019	39	-65	-50	-48	N/A
9/30/2019	23	-80	-62	-60	N/A
6/30/2019	8	-94	-73	-71	N/A
3/31/2019	8	-87	-66	-64	N/A
12/31/2018	7	-80	-59	-56	N/A
9/30/2018	7	-75	N/A	N/A	N/A
6/30/2018	7	-70	-58	-56	N/A
3/31/2018	7	-63	N/A	-53	N/A
12/31/2017	7	-56	N/A	-50	N/A
9/30/2017	7	-50	N/A	N/A	N/A
6/30/2017	8	-44	N/A	-40	N/A
3/31/2017	7	-39	N/A	-34	N/A
12/31/2016	7	-34	N/A	-27	N/A
9/30/2016	6	-27	N/A	-23	N/A
6/30/2016	5	-21	N/A	-18	N/A
3/31/2016	5	-19	N/A	-16	N/A
12/31/2015	4	-17	N/A	-15	N/A
9/30/2015	5	-17	N/A	-17	N/A
6/30/2015	5	-17	N/A	-19	N/A
3/31/2015	6	-17	N/A	-17	N/A
12/31/2014	7	-17	N/A	-15	N/A
9/30/2014	7	-15	N/A	-15	N/A
6/30/2014	7	-14	N/A	-14	N/A
3/31/2014	6	-13	N/A	-11	N/A
12/31/2013	6	-13	N/A	-9	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: GNFTDas prognostizierte Gewinnwachstum (41.2% pro Jahr) liegt über der Sparquote (1.4%).

Ertrag vs. Markt: GNFTDie Erträge des Unternehmens (41.2% pro Jahr) werden voraussichtlich schneller wachsen als der Markt French (12.5% pro Jahr).

Hohe Wachstumserträge: GNFTEs wird erwartet, dass die Erträge des Unternehmens in den nächsten 3 Jahren erheblich steigen werden.

Einnahmen vs. Markt: GNFTDie Einnahmen des Unternehmens (20.1% pro Jahr) werden voraussichtlich schneller wachsen als der Markt French (5.6% pro Jahr).

Hohe Wachstumseinnahmen: GNFTDie Einnahmen des Unternehmens (20.1% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: GNFTDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (5.5%).

Genfit Zukünftiges Wachstum

Future Kriterienprüfungen 5/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus EPS estimates increase by 21%, revenue downgraded

Consensus EPS estimates fall by 15%

Consensus revenue estimates increase by 38%, EPS downgraded

Consensus EPS estimates increase by 291%

Price target increased by 9.4% to €9.72

Consensus revenue estimates decrease by 21%

Recent updates

Genfit S.A. (EPA:GNFT) Not Doing Enough For Some Investors As Its Shares Slump 25%

Investor sentiment deteriorates as stock falls 20%

Consensus EPS estimates increase by 21%, revenue downgraded

We Think Shareholders Should Be Aware Of Some Factors Beyond Genfit's (EPA:GNFT) Profit

Investor sentiment improves as stock rises 26%

Genfit S.A. (EPA:GNFT) Held Back By Insufficient Growth Even After Shares Climb 26%

First half 2024 earnings: EPS and revenues exceed analyst expectations

Growth Investors: Industry Analysts Just Upgraded Their Genfit S.A. (EPA:GNFT) Revenue Forecasts By 28%

Genfit (EPA:GNFT) Seems To Use Debt Quite Sensibly

Genfit S.A. Announces the Successful Corporate Milestone with U.S. FDA Accelerated Approval of Ipsen's Iqirvo for Primary Biliary Cholangitis

New minor risk - Share price stability

Genfit S.A.'s (EPA:GNFT) Price Is Right But Growth Is Lacking After Shares Rocket 28%

Full year 2023 earnings: EPS and revenues miss analyst expectations

Insufficient new directors

New minor risk - Share price stability

Genfit S.A., Annual General Meeting, May 22, 2024

Genfit S.A.'s (EPA:GNFT) 26% Price Boost Is Out Of Tune With Revenues

Ipsen Confirms U.S. FDA Grants Priority Review for New Drug Application for Elafibranor for the Treatment of Rare, Cholestatic Liver Disease, PBC

Ipsen and GENFIT Announces Full Results from the Pivotal Phase III ELATIVE Trial

Consensus EPS estimates fall by 15%

Consensus revenue estimates increase by 38%, EPS downgraded

GENFIT Announces Publication in Nature Medicine Confirming the Performance of Its Nash Diagnostic Technology

First half 2023 earnings released: €0.42 loss per share (vs €0.21 loss in 1H 2022)

Health Check: How Prudently Does Genfit (EPA:GNFT) Use Debt?

New minor risk - Profitability

Consensus EPS estimates increase by 291%

Genfit S.A. Announces the Publication of New Data on the Clinical Performance of NIS2+(TM) in Older Patients in Hepatology Communications

New minor risk - Profitability

Price target increased by 9.4% to €9.72

Revenue Downgrade: Here's What Analysts Forecast For Genfit S.A. (EPA:GNFT)

Consensus revenue estimates decrease by 21%

Ipsen and GENFIT Announces Positive Results from Phase III ELATIVE Trial of Elafibranor in Patients with Primary Biliary Cholangitis, A Rare Cholestatic Liver Disease

Price target increased by 9.4% to €9.70

New minor risk - Share price stability

Genfit S.A. (EPA:GNFT) Investors Are Less Pessimistic Than Expected

Price target decreased by 11% to €8.84

GENFIT Presents Phase 1 Clinical Data Evaluating NTZ at Digestive Disease Week as part of its ACLF Program

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Price target decreased by 7.1% to €9.20

Genfit S.A. to Report First Half, 2023 Results on Sep 20, 2023

We Think Genfit (EPA:GNFT) Can Manage Its Debt With Ease

Consensus forecasts updated

New Forecasts: Here's What Analysts Think The Future Holds For Genfit S.A. (EPA:GNFT)

Genfit S.A. (ENXTPA:GNFT) acquired Versantis AG for approximately CHF 110 million.

First half 2022 earnings released: €0.21 loss per share (vs €0.21 profit in 1H 2021)

Genfit S.A. (ENXTPA:GNFT) agreed to acquire Versantis AG for approximately CHF 110 million.

Genfit S.A. (ENXTPA:GNFT) agreed to acquire Versantis AG from a group of investors for approximately CHF 110 million.

Consensus forecasts updated

Investor sentiment improved over the past week

Downgrade: Here's How Analysts See Genfit S.A. (EPA:GNFT) Performing In The Near Term

Consensus revenue estimates fall by 49%

Price target increased to €10.48

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Consensus revenue estimates increase by 1,016%

Forecast to breakeven in 2022

Consensus forecasts updated

First half 2021 earnings released: EPS €0.21 (vs €1.36 loss in 1H 2020)

GENFIT Presents New NIS4® Data in NASH at the International Liver Congress™ and the 81St Scientific Sessions of the American Diabetes Association

GENFIT Announces the Launch of NASHnext®, a Novel, Noninvasive Diagnostic Test for Nonalcoholic Steatohepatitis

Full year 2020 earnings released: €2.61 loss per share (vs €1.76 loss in FY 2019)

Price target increased to €8.30

Full year 2020 earnings released

Genfit's(EPA:GNFT) Share Price Is Down 85% Over The Past Five Years.

GENFIT Announces Board Changes

Genfit SA to Report Fiscal Year 2020 Results on Apr 01, 2021

Price target raised to €8.20

Genfit SA, Annual General Meeting, May 28, 2021

New 90-day high: €5.20

GENFIT Announces Publication of Positive Results from the Phase 2 Clinical Trial Evaluating Elafibranor in Patients with PBC in the Journal of Hepatology